2017
DOI: 10.1080/10245332.2017.1279842
|View full text |Cite
|
Sign up to set email alerts
|

Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era

Abstract: Outcomes of SMZL, in our series, were excellent, with a median OS of >13 years. Low hemoglobin and high-risk FLIPI were associated with inferior outcomes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0
4

Year Published

2018
2018
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 24 publications
0
5
0
4
Order By: Relevance
“…Patients with MALT lymphoma also had a superior outcome, especially when compared with patients with SMZL, attaining a 5‐year OS of 77% vs. 61% (data not shown). This survival advantage was achieved in spite of a comparable risk of relapse and NRM, suggesting that patients with MALT lymphoma who relapse following ASCT have a higher chance to be salvaged compared with patients with SMZL, probably reflecting the natural differences in the biology and clinical course between these MZL subtypes (Arcaini et al , ; Zinzani, ), although some studies, mainly performed in the rituximab era, proposed a non‐inferior outcome of SMZL compared with MALT lymphoma (Else et al , Starr et al , ). Another explanation would be patient selection for transplantation, given the retrospective nature of our study.…”
Section: Discussionmentioning
confidence: 99%
“…Patients with MALT lymphoma also had a superior outcome, especially when compared with patients with SMZL, attaining a 5‐year OS of 77% vs. 61% (data not shown). This survival advantage was achieved in spite of a comparable risk of relapse and NRM, suggesting that patients with MALT lymphoma who relapse following ASCT have a higher chance to be salvaged compared with patients with SMZL, probably reflecting the natural differences in the biology and clinical course between these MZL subtypes (Arcaini et al , ; Zinzani, ), although some studies, mainly performed in the rituximab era, proposed a non‐inferior outcome of SMZL compared with MALT lymphoma (Else et al , Starr et al , ). Another explanation would be patient selection for transplantation, given the retrospective nature of our study.…”
Section: Discussionmentioning
confidence: 99%
“…Hermine ve arkadaşlarının yapmış olduğu bir çalışmada ise HCV tedavisi ile dokuz SMZL'li hastanın yedisinde yanıt alındığı gösterilmiştir (4). Bu hastaların %6.3'ünde ise daha önceki serilerle Starr ve arkadaşlarının yapmış olduğu çalışmada, hastaların %4.7'si tedavisiz takip edilirken, İtalya'dan yeni yayınlanan 100 hastalık bir seride hastaların %30'u yaklaşık 10 yıl süreyle tedavisiz takip edilmiştir (8,12). Bizim hasta grubumuzda daha çok yaygın hastalık tutulumlu olgular olduğu için sadece 88 yaşında ve komorbiditeleri olan erken evre hastamızı tedavisiz takip edebildik.…”
Section: Tartişma Ve Sonuçunclassified
“…Splenik MZL tanısında, tedavi ihtiyacı olan ve randomize bir klinik çalışmaya dahil edilemeyecek hastalar için tedavi seçmek takip eden hekimin tercihine kalmaktadır. Avrupa'da splenektomi ilk seçenek olarak kullanılırken, Amerika Birleşik Devletleri'nde daha çok rituksimab monoterapisi tercih edilmektedir (8). Farklı merkezlerin tedavi seçeneklerini karşılaştırmak hastalık riskinin heterojenitesi nedeniyle zor olmaktadır.…”
Section: Tartişma Ve Sonuçunclassified
See 2 more Smart Citations